抗肿瘤血管生成药物不良反应的发生机制及处理  

Pathogenesis and Treatment Principle of Adverse Reactions of Anti-angiogenetic Drugs

作　　者：吴军[1] 王婧[1] 曹邦伟[1] 

机构地区：[1]首都医科大学附属北京友谊医院肿瘤科

出　　处：《医学综述》2016年第16期3154-3157,共4页Medical Recapitulate

基　　金：国家自然科学基金(81272615);北京市医院管理局"青苗"计划专项经费资助(QML20150107);北京市中医药科技发展资金(QN2015-08);首都医科大学附属北京友谊医院院科研启动基金(yyqdkt2014-10)

摘　　要：血管生成是恶性肿瘤发生、发展及转移的重要机制之一,抗血管生成治疗是肿瘤分子靶向治疗的重要策略。目前常用的治疗药物主要包括以贝伐单抗为代表的单克隆抗体类,以索拉菲尼、舒尼替尼、阿帕替尼等为代表的酪氨酸激酶抑制剂类,以及部分中药。不同种类药物的不良反应及其发生率不同,了解药物不良反应的发生机制及处理原则,将会提高患者用药的耐受性及改善预后。Angiogenesis plays a very important role in tumor pathogenesis, development and metastasis. Inhibiting angiogenesis has become a successful strategy in tumor molecular-targeting therapy. The anti-angio- genic drugs mainly include the monoclonal antibody like bevacizumab and the tyrosine kinase inhibitors such as serafanib, sunitinib and apatinib. Some Chinese medical herbs are also used as anti-angiogenic drugs. How- ever, different kinds of anti-angiogenie drugs have different adverse effects and different incidences. It＇s important to know the adverse effects and the corresponding principle of treatment, which will improve the patient＇s tolerance and prognosis.

关 键 词：肿瘤 抗血管生成药物 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]